Vigil Neuroscience (VIGL) announced an update on the Phase 2 IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. Iluzanebart demonstrated a favorable safety, tolerability and pharmacokinetic profile across both the 20 mg/kg and 40 mg/kg dose cohorts. The Phase 2 IGNITE trial showed no beneficial effects on biomarker or clinical efficacy endpoints with treatment of iluzanebart in ALSP patients. Based upon these results, the Phase 2 long-term extension study is being discontinued in accordance with the process previously disclosed.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Neuroscience downgraded to Hold from Buy at Stifel
- Hold Rating on Vigil Neuroscience Amid Sanofi Acquisition and VG-3927 Developments
- Vigil Neuroscience downgraded to Neutral from Buy at H.C. Wainwright
- Vigil Neuroscience Elects Directors at Annual Meeting
- Vigil Neuroscience downgraded to Neutral from Outperform at Mizuho
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue